Zevra Therapeutics
ZVRA
38 hedge funds and large institutions have $16.5M invested in Zevra Therapeutics in 2018 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 15 increasing their positions, 4 reducing their positions, and 5 closing their positions.
275% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 4
100% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 5
15% more funds holding
Funds holding: 33 → 38 (+5)
33% less capital invested
Capital invested by funds: $24.4M → $16.5M (-$7.97M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $2K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DA
DSC Advisors
Chicago,
Illinois
|
+$5.06M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
+$3.73M |
| 3 |
CI
Cowen Inc
New York
|
+$506K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$250K |
| 5 |
JGC
J. Goldman & Co
New York
|
+$228K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$498K |
| 2 |
Morgan Stanley
New York
|
-$59.5K |
| 3 |
Wells Fargo
San Francisco,
California
|
-$41.7K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
-$28.3K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$16.1K |
ZVRA Hedge Fund Activity: Q4 2018 in Review
38 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Zevra Therapeutics (ZVRA) for Q4 2018, worth a combined $16.5M — down 33% from $24.4M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new ZVRA positions and 5 closed out — a net gain of 5 holders — while 15 added to existing stakes and 4 trimmed.
The largest buyer was DSC Advisors, adding an estimated $5.06M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $498K sold.
- 38 institutional investors held Zevra Therapeutics (ZVRA) as of Q4 2018, up from 33 in Q3 2018.
- Funds reported $16.5M of Zevra Therapeutics stock for Q4 2018, down 33% quarter-over-quarter.
- 10 funds opened new Zevra Therapeutics positions in Q4 2018 and 5 closed out, a net change of +5 holders.
- The largest Zevra Therapeutics buyer in Q4 2018 was DSC Advisors, an estimated $5.06M added.
- The largest Zevra Therapeutics seller in Q4 2018 was Renaissance Technologies, an estimated $498K sold.
Based on aggregated 13F filings for Q4 2018.